Lavomax 3's 125 mg coated tablets
- $16.90
Trade name
of Lavomaks®
the International unlicensed
name Tiloron Lekarstvennaya
the Tablet form, coated, 125 mg
Structure
One tablet contains
active agent – a tiloron dihydrochloride of 125 mg,
excipients:
kernel: hydroxycarbonate magnesium pentahydrate, povidone, calcium stearate,
cover: sucrose, povidone, kopovidon, hydroxycarbonate magnesium pentahydrate, the titan dioxide (E 171), silicon dioxide colloidal (A-380 aerosil), tropeolin - Oh, a macrogoal-6000, beeswax, liquid paraffin, talc.
The description
of the Tablet, coated, from yellow till orange color, round shape. Kernel of a tablet of orange color.
The pharmacotherapeutic group
Antiviral drugs other
the ATX J05AX Code
the Pharmacological
Pharmacokinetics Later properties of intake tiloron is quickly soaked up from digestive tract. The bioavailability is 60%. About 80% of a tiloron contact proteins of blood plasma.
It is removed tiloron practically in not changed view with a stake (70%) and urine (9%). Elimination half-life (T1/2) makes 48 hours. Tiloron is not exposed to biotransformation and does not collect in an organism.
The pharmacodynamics
of Lavomaks® stimulates education in an organism α, β and γ-interferon. The main producers of interferon in response to introduction of a tiloron are intestines epithelium cells, hepatocytes, T lymphocytes and neutrophils. After intake at most of products of interferon is defined in the sequence – intestines-liver-blood in 4-24 hours. Tiloron has immunomodulatory and antiviral effect. Stimulates stem cells of marrow, strengthens antibodyformation, reduces immunosuppression degree, restores a ratio T-helpery/T-supressory. It is effective against various viral infections, including against influenza viruses, other acute respiratory infections, viruses of hepatitis, gerpesvirus, cytomegaloviruses and neurotropic viruses. The mechanism of anti-virus action is connected with inhibition of broadcast of virus-specific proteins in the infected cells therefore the reproduction of viruses is suppressed.
Indications
At adults:
as a part of complex therapy of a viral hepatitis And
as a part of complex therapy of herpetic, Cytomegaloviral infections
as a part of complex therapy of infectious and allergic and viral encephalomyelitis (multiple sclerosis, leukoencephalites, uveoentsefalita, etc.)
as a part of complex therapy of urogenital and respiratory clamidiosis, not gonococcal uretrit, a pulmonary tuberculosis (at the proved immune insufficiency)
treatment and prevention of flu and other acute respiratory viral infections (ARVI)
the Route of administration and doses
use Drug inside, after a meal.
As a part of complex therapy on doctor's orders:
In a viral hepatitis And – the first day on 1 tablet (that corresponds to 125 mg of a tiloron) 2 times a day, then on 1 tablet every 48 hours. A course dose – 10 tablets (that corresponds to 1.25 g of a tiloron).
At treatment of flu and other SARS – in the first two days of a disease appoint on 1 tablet (that corresponds to 125 mg of a tiloron) a day, then on 1 tablet (125 mg) every 48 hours. A course dose – 6 tablets (that corresponds to 750 mg of a tiloron).
For prevention of flu and other SARS appoint on 1 tablet Lavomaksa® (125 mg) once a week within 6 weeks (to a course of treatment – 6 tablets on 125 mg).
In a herpes and Cytomegaloviral infection – the first two days accept on 1 tablet Lavomaksa® (125 mg) a day, then, on 1 tablet (125 mg) every 48 hours. A course dose – 20 tablets Lavomaksa® (that corresponds to 2.5 g of a tiloron).
In urogenital and respiratory clamidiosis – the first two days accept on 1 tablet Lavomaksa® (that corresponds to 125 mg of a tiloron) a day, then on 1 tablet (125 mg) every 48 hours. A course dose – 10 tablets Lavomaksa® (that corresponds to 1.25 g of a tiloron).
In a pulmonary tuberculosis – the first two days accept 2 tablets (that corresponds to 250 mg of a tiloron) a day, then on 1 tablet (125 mg) in each 48 h. A course dose – 20 tablets Lavomaksa® (that corresponds to 2.5 g of a tiloron), within 36 days.
In infectious and allergic and viral encephalomyelitis – the dose is established individually, the course of treatment makes 4 weeks.
Side effects
allergic reactions
the dispeptic phenomena
a short-term fever
of the Contraindication
hypersensitivity to drug components
the period of pregnancy and a lactation
children's age up to 18 years
the deficiency of invertase/isomaltase, intolerance of fructose, glyukozo-galaktozny malabsorption (drug contains sucrose)
Medicinal interactions
of Lavomaks® is compatible to antibiotics and means of traditional treatment of viral and bacterial diseases.
Clinically significant interaction of Lavomaksa® with antibiotics and means of traditional treatment of viral and bacterial diseases, alcohol is not revealed.
Special indications
of Feature of influence of medicine on ability to drive the car or potentially dangerous mechanisms
does not influence ability to run the vehicle or potentially dangerous mechanisms.
Overdose
Cases of overdose of Lavomaksa® are unknown.
The form of release and packing
On 3, 6 or 10 tablets place in blister strip packaging from a film of the polyvinylchloride and printing aluminum foil varnished.
On 1 planimetric packing together with the instruction for medical use in the state and Russian languages put in a pack from cardboard.
To Store storage conditions in the dry, protected from light place at a temperature not above 25 °C.
To store out of children's reach!
2 years
not to apply a period of storage after an expiration date.
Prescription status
Without prescription
of Lavomaks®
the International unlicensed
name Tiloron Lekarstvennaya
the Tablet form, coated, 125 mg
Structure
One tablet contains
active agent – a tiloron dihydrochloride of 125 mg,
excipients:
kernel: hydroxycarbonate magnesium pentahydrate, povidone, calcium stearate,
cover: sucrose, povidone, kopovidon, hydroxycarbonate magnesium pentahydrate, the titan dioxide (E 171), silicon dioxide colloidal (A-380 aerosil), tropeolin - Oh, a macrogoal-6000, beeswax, liquid paraffin, talc.
The description
of the Tablet, coated, from yellow till orange color, round shape. Kernel of a tablet of orange color.
The pharmacotherapeutic group
Antiviral drugs other
the ATX J05AX Code
the Pharmacological
Pharmacokinetics Later properties of intake tiloron is quickly soaked up from digestive tract. The bioavailability is 60%. About 80% of a tiloron contact proteins of blood plasma.
It is removed tiloron practically in not changed view with a stake (70%) and urine (9%). Elimination half-life (T1/2) makes 48 hours. Tiloron is not exposed to biotransformation and does not collect in an organism.
The pharmacodynamics
of Lavomaks® stimulates education in an organism α, β and γ-interferon. The main producers of interferon in response to introduction of a tiloron are intestines epithelium cells, hepatocytes, T lymphocytes and neutrophils. After intake at most of products of interferon is defined in the sequence – intestines-liver-blood in 4-24 hours. Tiloron has immunomodulatory and antiviral effect. Stimulates stem cells of marrow, strengthens antibodyformation, reduces immunosuppression degree, restores a ratio T-helpery/T-supressory. It is effective against various viral infections, including against influenza viruses, other acute respiratory infections, viruses of hepatitis, gerpesvirus, cytomegaloviruses and neurotropic viruses. The mechanism of anti-virus action is connected with inhibition of broadcast of virus-specific proteins in the infected cells therefore the reproduction of viruses is suppressed.
Indications
At adults:
as a part of complex therapy of a viral hepatitis And
as a part of complex therapy of herpetic, Cytomegaloviral infections
as a part of complex therapy of infectious and allergic and viral encephalomyelitis (multiple sclerosis, leukoencephalites, uveoentsefalita, etc.)
as a part of complex therapy of urogenital and respiratory clamidiosis, not gonococcal uretrit, a pulmonary tuberculosis (at the proved immune insufficiency)
treatment and prevention of flu and other acute respiratory viral infections (ARVI)
the Route of administration and doses
use Drug inside, after a meal.
As a part of complex therapy on doctor's orders:
In a viral hepatitis And – the first day on 1 tablet (that corresponds to 125 mg of a tiloron) 2 times a day, then on 1 tablet every 48 hours. A course dose – 10 tablets (that corresponds to 1.25 g of a tiloron).
At treatment of flu and other SARS – in the first two days of a disease appoint on 1 tablet (that corresponds to 125 mg of a tiloron) a day, then on 1 tablet (125 mg) every 48 hours. A course dose – 6 tablets (that corresponds to 750 mg of a tiloron).
For prevention of flu and other SARS appoint on 1 tablet Lavomaksa® (125 mg) once a week within 6 weeks (to a course of treatment – 6 tablets on 125 mg).
In a herpes and Cytomegaloviral infection – the first two days accept on 1 tablet Lavomaksa® (125 mg) a day, then, on 1 tablet (125 mg) every 48 hours. A course dose – 20 tablets Lavomaksa® (that corresponds to 2.5 g of a tiloron).
In urogenital and respiratory clamidiosis – the first two days accept on 1 tablet Lavomaksa® (that corresponds to 125 mg of a tiloron) a day, then on 1 tablet (125 mg) every 48 hours. A course dose – 10 tablets Lavomaksa® (that corresponds to 1.25 g of a tiloron).
In a pulmonary tuberculosis – the first two days accept 2 tablets (that corresponds to 250 mg of a tiloron) a day, then on 1 tablet (125 mg) in each 48 h. A course dose – 20 tablets Lavomaksa® (that corresponds to 2.5 g of a tiloron), within 36 days.
In infectious and allergic and viral encephalomyelitis – the dose is established individually, the course of treatment makes 4 weeks.
Side effects
allergic reactions
the dispeptic phenomena
a short-term fever
of the Contraindication
hypersensitivity to drug components
the period of pregnancy and a lactation
children's age up to 18 years
the deficiency of invertase/isomaltase, intolerance of fructose, glyukozo-galaktozny malabsorption (drug contains sucrose)
Medicinal interactions
of Lavomaks® is compatible to antibiotics and means of traditional treatment of viral and bacterial diseases.
Clinically significant interaction of Lavomaksa® with antibiotics and means of traditional treatment of viral and bacterial diseases, alcohol is not revealed.
Special indications
of Feature of influence of medicine on ability to drive the car or potentially dangerous mechanisms
does not influence ability to run the vehicle or potentially dangerous mechanisms.
Overdose
Cases of overdose of Lavomaksa® are unknown.
The form of release and packing
On 3, 6 or 10 tablets place in blister strip packaging from a film of the polyvinylchloride and printing aluminum foil varnished.
On 1 planimetric packing together with the instruction for medical use in the state and Russian languages put in a pack from cardboard.
To Store storage conditions in the dry, protected from light place at a temperature not above 25 °C.
To store out of children's reach!
2 years
not to apply a period of storage after an expiration date.
Prescription status
Without prescription
Related Products
